Genentech, Inc.

Lin, Kui

Punnoose, Elizabeth

Seshagiri, Somasekar

Kui Lin

Deepak Sampath

Somasekar Seshagiri

Michelle Nannini

Elizabeth Punnoose

Jeffrey Wallin

Premal Patel

Brian Lee

Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant

Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.

Methods and compositions for detecting and treating drug resistant AKT mutant

The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R, R, R, R, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use

The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer. 

Combinations of AKT and MEK inhibitor compounds, and methods of use

Growing community of inventors

South San Francisco, CA, United States of America

Kui Lin